Tempest Therapeutics, Inc. — Director's Dealing 2015

Jul 3, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2015-06-30

Reporting Person: Dipp Michelle (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-30	Common Stock	F	1256	$28.93	Disposed	986457	Direct

Footnotes

F1: Shares withheld by the Registrant to satisfy minimum statutory withholding requirements upon vesting of time-based RSUs.

F2: Represents 963,279 shares of common stock and 23,178 RSUs.